PD-1-Blockade bei einem HIV-Patienten mit metastasiertem Merkelzellkarzinom
Research output: Contribution to journal › Research article › Contributed
Contributors
Abstract
Due to modern antiretroviral therapy (ART), HIV-positive patients have an almost normal life expectancy. The result is an increase in non-HIV-associated cancers among HIV-infected patients. The effects and side effects of the new checkpoint inhibitors, e.g. anti-PD-1 antibodies (PD1 AK) in HIV-infected patients with an altered immune system have not yet been sufficiently investigated. In the presented case report, a patient with metastatic Merkel cell carcinoma and a newly diagnosed HIV infection was treated with an antiretroviral therapy and pembrolizumab. Therapy with the anti-PD-1 antibody showed a complete remission after 6 months and a rapid improvement of the immune status. Treatment of an HIV-infected patient with PD-1 antibodies appears to be effective and tolerable and does not appear to have a negative effect on the course of the HIV infection. Thus, anti-PD-1 antibodies are a therapeutic option for HIV-positive patients with metastatic Merkel cell carcinoma.
Translated title of the contribution | PD-1 Blockade in an HIV Patient with Metastatic Merkel Cell Carcinoma |
---|
Details
Original language | German |
---|---|
Pages (from-to) | 268-272 |
Number of pages | 5 |
Journal | Aktuelle Dermatologie |
Volume | 44 |
Issue number | 6 |
Publication status | Published - 1 Jun 2018 |
Peer-reviewed | No |
External IDs
ORCID | /0000-0001-7096-5199/work/155291459 |
---|---|
ORCID | /0009-0001-4054-4024/work/155291693 |
ORCID | /0000-0003-4340-9706/work/155292317 |
ORCID | /0000-0002-2164-4644/work/155292403 |